This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furukawa, T. Articles by Tsao, M. S. Search for Related Content PubMed PubMed Citation Articles by Furukawa, T. Articles by Tsao, M. S.

American Journal of Pathology, Vol 147, 889-895, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis

T Furukawa, WP Duguid, M Kobari, S Matsuno and MS Tsao
Department of Pathology, Montreal General Hospital/Research Institute, Quebec, Canada.

We have used immunohistochemistry to evaluate the clinicopathological significance of hepatocyte growth factor (HGF) and Met/HGF receptor expression in ductal lesions of 46 human pancreata. Normal duct epithelium shows no significant immunoreactivity for either HGF or Met. Strong immunostaining for HGF was respectively demonstrated in hyperplastic and severely dysplastic epithelia in 35.5 and 40% of cases with such duct lesions, whereas 37% of ductal adenocarcinoma showed diffuse HGF immunostaining. Positive Met immunostaining was demonstrated in 58, 80, and 78%, respectively, of specimens demonstrating the above duct lesions. Patients with resectable ductal adenocarcinoma demonstrating diffuse Met immunostaining have a significantly longer survival than those with tumors showing negative/focal staining (19.7 versus 8.1 months at P = 0.026). In contrast, HGF immunoreactivity did not significantly correlate with the survival of the patients. The results suggest that HGF and Met expression may play significant bifunctional roles during human pancreatic ductal carcinogenesis and progression. Whereas an upregulation of Met receptor expression and HGF-Met interaction may have an important pathogenetic role during the early stages of neoplastic promotion, a lack or subsequent loss of Met expression in invasive adenocarcinoma appears to result in a more aggressive clinical behavior.

This article has been cited by other articles:

				H. Jin, R. Yang, Z. Zheng, M. Romero, J. Ross, H. Bou-Reslan, R. A.D. Carano, I. Kasman, E. Mai, J. Young, et al. MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival Cancer Res., June 1, 2008; 68(11): 4360 - 4368. [Abstract] [Full Text] [PDF]

				J. M. Siegfried, C. T. Gubish, M. E. Rothstein, P. E. Q. de Oliveira, and L. P. Stabile Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non Small-Cell Lung Cancer Mol. Pharmacol., September 1, 2007; 72(3): 769 - 779. [Abstract] [Full Text] [PDF]

				C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198. [Abstract] [Full Text] [PDF]

				K. M. Hoffmann, J. A. Tapia, M. J. Berna, M. Thill, T. Braunschweig, S. A. Mantey, T. W. Moody, and R. T. Jensen Gastrointestinal Hormones Cause Rapid c-Met Receptor Down-regulation by a Novel Mechanism Involving Clathrin-mediated Endocytosis and a Lysosome-dependent Mechanism J. Biol. Chem., December 8, 2006; 281(49): 37705 - 37719. [Abstract] [Full Text] [PDF]

				A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]

				R. Mineo, A. Costantino, F. Frasca, L. Sciacca, S. Russo, R. Vigneri, and A. Belfiore Activation of the Hepatocyte Growth Factor (HGF)-Met System in Papillary Thyroid Cancer: Biological Effects of HGF in Thyroid Cancer Cells Depend on Met Expression Levels Endocrinology, September 1, 2004; 145(9): 4355 - 4365. [Abstract] [Full Text] [PDF]

				A. Suzuki, H. Nakauchi, and H. Taniguchi Prospective Isolation of Multipotent Pancreatic Progenitors Using Flow-Cytometric Cell Sorting Diabetes, August 1, 2004; 53(8): 2143 - 2152. [Abstract] [Full Text] [PDF]

				S. Yoshida, T. Harada, T. Iwabe, F. Taniguchi, A. Fujii, Y. Sakamoto, N. Yamauchi, G. Shiota, and N. Terakawa Induction of Hepatocyte Growth Factor in Stromal Cells by Tumor-Derived Basic Fibroblast Growth Factor Enhances Growth and Invasion of Endometrial Cancer J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2376 - 2383. [Abstract] [Full Text] [PDF]

				Y. C. Hu, K. Y. Lam, S. Law, J. Wong, and G. Srivastava Profiling of Differentially Expressed Cancer-related Genes in Esophageal Squamous Cell Carcinoma (ESCC) Using Human Cancer cDNA Arrays: Overexpression of Oncogene MET Correlates with Tumor Differentiation in ESCC Clin. Cancer Res., November 1, 2001; 7(11): 3519 - 3525. [Abstract] [Full Text] [PDF]

				D. Tomioka, N. Maehara, K. Kuba, K. Mizumoto, M. Tanaka, K. Matsumoto, and T. Nakamura Inhibition of Growth, Invasion, and Metastasis of Human Pancreatic Carcinoma Cells by NK4 in an Orthotopic Mouse Model Cancer Res., October 1, 2001; 61(20): 7518 - 7524. [Abstract] [Full Text] [PDF]

				T. Horikawa, T.-S. Sheen, H. Takeshita, H. Sato, M. Furukawa, and T. Yoshizaki Induction of c-Met Proto-Oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the Correlation with Cervical Lymph Node Metastasis of Nasopharyngeal Carcinoma Am. J. Pathol., July 1, 2001; 159(1): 27 - 33. [Abstract] [Full Text] [PDF]

				K.-i. Nakashiro, M. Okamoto, Y. Hayashi, and R. Oyasu Hepatocyte Growth Factor Secreted by Prostate-Derived Stromal Cells Stimulates Growth of Androgen-Independent Human Prostatic Carcinoma Cells Am. J. Pathol., September 1, 2000; 157(3): 795 - 803. [Abstract] [Full Text] [PDF]

				A. Garcia-Ocana, K. K. Takane, M. A. Syed, W. M. Philbrick, R. C. Vasavada, and A. F. Stewart Hepatocyte Growth Factor Overexpression in the Islet of Transgenic Mice Increases Beta Cell Proliferation, Enhances Islet Mass, and Induces Mild Hypoglycemia J. Biol. Chem., January 14, 2000; 275(2): 1226 - 1232. [Abstract] [Full Text] [PDF]

				R. van der Voort, T. E. I. Taher, V. J. M. Wielenga, M. Spaargaren, R. Prevo, L. Smit, G. David, G. Hartmann, E. Gherardi, and S. T. Pals Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met J. Biol. Chem., March 5, 1999; 274(10): 6499 - 6506. [Abstract] [Full Text] [PDF]

				R. Paciucci, M. R. Vila, T. Adell, V. M. Diaz, M. Tora, T. Nakamura, and F. X. Real Activation of the Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor System and Redistribution of E-Cadherin Are Associated with Hepatocyte Growth Factor-Induced Motility of Pancreas Tumor Cells Overexpressing Met Am. J. Pathol., July 1, 1998; 153(1): 201 - 212. [Abstract] [Full Text] [PDF]

				N. Liu, T. Furukawa, M. Kobari, and M.-S. Tsao Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma Am. J. Pathol., July 1, 1998; 153(1): 263 - 269. [Abstract] [Full Text] [PDF]

				A. Belfiore, P. Gangemi, A. Costantino, G. Russo, G. M. Santonocito, O. Ippolito, M. F. Di Renzo, P. Comoglio, A. Fiumara, and R. Vigneri Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2322 - 2328. [Abstract] [Full Text] [PDF]

				J. Y. Ljubimova, L. M. Petrovic, S. E. Wilson, S. A. Geller, and A. A. Demetriou Expression of HGF, Its Receptor c-met, c-myc, and Albumin in Cirrhotic and Neoplastic Human Liver Tissue J. Histochem. Cytochem., January 1, 1997; 45(1): 79 - 88. [Abstract] [Full Text] [PDF]